Department of Radiology, Tenon Hospital, and Pierre et Marie Curie University, 4 rue de la Chine, 75020 Paris, France.
AJR Am J Roentgenol. 2012 Jan;198(1):207-12. doi: 10.2214/AJR.10.5370.
The purpose of this study was to evaluate the feasibility and efficacy of pulmonary artery occlusion with ethylene vinyl alcohol copolymer in patients with hemoptysis.
We reviewed the cases of 12 consecutively registered patients (10 men, two women; age range, 21-83 years; mean, 54.5 years) who were treated for hemoptysis by pulmonary artery occlusion with ethylene vinyl alcohol copolymer. The indications, immediate hemoptysis control, and clinical tolerability were analyzed.
The underlying diseases were necrotizing pneumonia in four patients, necrotizing aspergillosis in one patient, complex aspergilloma in two patients, active tuberculosis in two patients, lung cancer in two patients, and Behçet disease in one patient. Ethylene vinyl alcohol copolymer was used alone in nine patients and with steel coils in three patients. The main indications were a small-necked pulmonary artery pseudoaneurysm in five patients, necrotic process in four patients, presence of systemic reperfusion of a pulmonary artery pseudoaneurysm in one patient, absolute necessity for anticoagulation therapy in one patient, and need to complete pulmonary artery aneurysm sac occlusion in one patient. The injection procedure was well tolerated. Hemoptysis of pulmonary arterial origin was controlled in all but one patient, who had progression of the infectious disease and underwent surgery. In two patients, hemoptysis recurred from systemic arteries and was treated with embolization of the systemic arteries in one patient and surgery in the other patient.
Ethylene vinyl alcohol copolymer embolization for hemoptysis of pulmonary arterial origin is feasible and efficacious. Use of this embolization agent is beneficial in patients with pulmonary artery injuries, especially those with small-necked lesions.
本研究旨在评估聚乙烯醇(ethylene vinyl alcohol copolymer,EVOH)胶栓塞肺动脉治疗咯血的可行性和疗效。
我们回顾性分析了 12 例连续登记的咯血患者(10 例男性,2 例女性;年龄 21~83 岁,平均 54.5 岁)接受 EVOH 胶栓塞肺动脉治疗的病例。分析了适应证、即刻咯血控制情况和临床耐受性。
基础疾病为坏死性肺炎 4 例,坏死性曲霉菌病 1 例,复杂曲霉菌瘤 2 例,活动性肺结核 2 例,肺癌 2 例,贝赫切特病 1 例。9 例单独使用 EVOH 胶,3 例与钢圈联合使用。主要适应证为 5 例肺动脉假性动脉瘤小瘤颈、4 例坏死病灶、1 例肺动脉假性动脉瘤全身再灌注、1 例绝对需要抗凝治疗、1 例需要完全闭塞肺动脉瘤囊。注射过程均耐受良好。除 1 例因感染性疾病进展而行手术治疗的患者外,所有患者的咯血均来自肺动脉。2 例患者出现系统性动脉出血,1 例采用系统性动脉栓塞治疗,另 1 例采用手术治疗。
EVOH 胶栓塞治疗肺动脉来源的咯血是可行且有效的。对于肺动脉损伤患者,尤其是小瘤颈病变患者,使用这种栓塞剂是有益的。